The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

There is positive data from other programs such as the oral amycretin candidate and more data are expected in the following ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...